Advertiser / Brand · vs · Data Provider / Broker · AdTech Vendor
Humana vs PurpleLab
Structured technology and market comparison · 2026
Direct Feature Comparison
Humana · vs · PurpleLabUS health insurer focused on Medicare and integrated care.
Healthcare data and analytics platform for research and advertising.
Analyze all overlapping signals and tech stacks for Humana and PurpleLab
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Humana and PurpleLab?
When comparing Humana and PurpleLab, both platforms operate within the Advertiser / Brand and Data Provider / Broker · AdTech Vendor ecosystem. Humana is positioned as US health insurer focused on Medicare and integrated care, whereas PurpleLab focuses on Healthcare data and analytics platform for research and advertising. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Humana and PurpleLab?
When evaluating Humana and PurpleLab, enterprise buyers also consider other platforms in Advertiser / Brand and Data Provider / Broker · AdTech Vendor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Humana and PurpleLab compare?
Humana is headquartered in US (founded in 1961) with >5,000 employees. PurpleLab is based in US (founded in 2015) with 10–49 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Humana vs PurpleLab
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Humana
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Humana (2026-10-13)
On October 13, 2026, Humana Inc. announced a new joint venture arrangement with funds managed by HPS Investment Partners, a subsidiary of BlackRock, Inc., to manage and operate its CenterWell Senior Primary Care clinic network. This arrangement replaces CenterWell's existing joint venture with Welsh, Carson, Anderson & Stowe (WCAS), with BlackRock acquiring WCAS's equity stake under modified terms. Notably, the new JV eliminates the previous put option held by WCAS, resulting in an expected significant reduction in balance sheet liabilities and a lower overall cost of capital. Concurrently, Humana reaffirmed its FY 2026 Adjusted EPS guidance of at least $9.00.
- BlackRock subsidiary HPS Investment Partners acquired WCAS's equity stake in CenterWell Senior Primary Care clinics under a restructured joint venture eliminating previous put option liabilities.
- CenterWell secures the option to purchase clinics starting in 2028, with BlackRock holding exit rights via a sale process by end-2033 if clinics remain unacquired.
- Humana reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 per common share.
- ·SEC APIfinancials
8-K Financial Filing Analysis for Humana (2026-10-09)
Humana Inc. announced that it has exceeded its goal of Top Quartile results for the 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028), based on final data released by the Centers for Medicare and Medicaid Services (CMS) on October 8, 2026. Top Quartile performance is defined as Stars revenue per member per month (PMPM) at least 10% above the peer group median. While anticipating that a portion of the 2028 bonus outperformance will be one-time in nature, Humana expects to utilize the resulting financial benefit for one-time investments and capital returns to shareholders. Concurrently, the company reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 and announced a virtual investor update scheduled for December 10, 2026.
- Exceeded the Top Quartile target for 2027 CMS Medicare Advantage Star Ratings (Bonus Year 2028), defined as Stars revenue PMPM 10% above the peer group median.
- Reaffirmed full-year 2026 Adjusted EPS guidance of at least $9.00 per share.
- Scheduled a virtual investor update for December 10, 2026, to review progress against the multi-year earnings framework through 2028.
- ·Humana
Humana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027
Press Release | 10/01/2026 Humana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027
PurpleLab
Recent Signals
- ·PurpleLab
PurpleLab Recognized as a 2026 AdExchanger Awards Finalist in Measurement and Analytics
PurpleLab has been named a finalist in the 2026 AdExchanger Awards in the Measurement and Analytics category, highlighting its recognition in the industry.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Humana and PurpleLab share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks